Results 251 to 260 of about 467,481 (433)

FOR THE COSMETICS INDUSTRY [PDF]

, 1966

openalex   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Rapid UHPLC-MS/MS Detection of Prohibited Drugs in Cosmetics Using Pass-Through SPE. [PDF]

ACS Omega
Mao J, Peng J, Zhu Y, Jiang X, Cao Y, Zhao T, Dong S, Dong F, He K, Wang N.   +9 more
europepmc   +1 more source

COSMETIC SURGERY For Small Breasts

, 1961
Thomas J. Baker
openalex   +1 more source

Cosmetics

Journal of AOAC INTERNATIONAL, 1991
openaire   +1 more source

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

Molecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren, Kathryn A. Wierenga, Frank M. Riemers, Elsbeth A. van Liere, Bart Westendorp   +4 more
wiley   +1 more source

Cosmetics Utilization Pattern, Perceived Adverse Effects and Identified Factors Among Final Year Under Graduate Female Students, University of Gondar, Ethiopia. [PDF]

J Cosmet Dermatol
Chanie GS, Simegn W, Gedu M, Nega T, Chekol N, Birhanu Z.   +5 more
europepmc   +1 more source

Report on Cosmetics [PDF]

, 1968
S H Newburger
openalex   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

The Pattern of Use of Cosmetics and Awareness of Cosmetovigilance Among Medical Students in Puducherry: A Cross-Sectional Study. [PDF]

Cureus
Abiramy P, Maharani B, Saritha M, Mathiyalagen P.   +3 more
europepmc   +1 more source